Literature DB >> 20307792

Study results from the Clinical Trials Network's first 10 years: where do they lead?

Elizabeth A Wells1, Andrew J Saxon, Donald A Calsyn, Thomas R Jackson, Dennis M Donovan.   

Abstract

The National Drug Abuse Treatment Clinical Trials Network (CTN) began in 2000 with the goal of "improv[ing] the quality of drug abuse treatment throughout the country using science as the vehicle." Since then, 24 discrete clinical trials were launched, 20 are completed, and 15 have published main outcome papers. Of the latter, 4 tested pharmacological treatment, 8 psychosocial/behavioral treatment, 1 a combination of medication and counseling, and 2 targeted HIV/hepatitis C virus risk behavior. We review main study findings for these trials, including treatment retention, substance use or risk behavior outcomes, and secondary outcomes when analyzed. The purpose of this review is to identify the incremental progress toward improving drug treatment made by these trials and to propose next steps for the CTN and for the field arising from these studies. The CTN provides a unique opportunity to systematically design trials that incorporate treatment improvements from previous trials and to direct efforts toward innovations most likely to be incorporated into practice.

Entities:  

Mesh:

Year:  2010        PMID: 20307792      PMCID: PMC2909697          DOI: 10.1016/j.jsat.2009.12.009

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  40 in total

Review 1.  A comprehensive guide to the application of contingency management procedures in clinical settings.

Authors:  N M Petry
Journal:  Drug Alcohol Depend       Date:  2000-02-01       Impact factor: 4.492

2.  A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.

Authors:  D E Jorenby; S J Leischow; M A Nides; S I Rennard; J A Johnston; A R Hughes; S S Smith; M L Muramoto; D M Daughton; K Doan; M C Fiore; T B Baker
Journal:  N Engl J Med       Date:  1999-03-04       Impact factor: 91.245

Review 3.  Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs.

Authors:  Andrew J Saxon; Dennis McCarty
Journal:  Pharmacol Ther       Date:  2005-10       Impact factor: 12.310

Review 4.  Detrimental effects of reward. Reality or myth?

Authors:  R Eisenberger; J Cameron
Journal:  Am Psychol       Date:  1996-11

5.  A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network.

Authors:  Walter Ling; Leslie Amass; Steve Shoptaw; Jeffrey J Annon; Maureen Hillhouse; Dean Babcock; Greg Brigham; Judy Harrer; Malcolm Reid; Joan Muir; Betty Buchan; Debbie Orr; George Woody; Jonathan Krejci; Douglas Ziedonis
Journal:  Addiction       Date:  2005-08       Impact factor: 6.526

Review 6.  Behavioral therapies for drug abuse.

Authors:  Kathleen M Carroll; Lisa S Onken
Journal:  Am J Psychiatry       Date:  2005-08       Impact factor: 18.112

Review 7.  Bridging the gap: a hybrid model to link efficacy and effectiveness research in substance abuse treatment.

Authors:  Kathleen M Carroll; Bruce J Rounsaville
Journal:  Psychiatr Serv       Date:  2003-03       Impact factor: 3.084

8.  Cognitive-behavioral intervention increases abstinence rates for depressive-history smokers.

Authors:  S M Hall; R F Muñoz; V I Reus
Journal:  J Consult Clin Psychol       Date:  1994-02

9.  Promising treatments for women with comorbid PTSD and substance use disorders.

Authors:  Denise A Hien; Lisa R Cohen; Gloria M Miele; Lisa Caren Litt; Carrie Capstick
Journal:  Am J Psychiatry       Date:  2004-08       Impact factor: 18.112

10.  A multisite randomized effectiveness trial of motivational enhancement therapy for Spanish-speaking substance users.

Authors:  Kathleen M Carroll; Steve Martino; Samuel A Ball; Charla Nich; Tami Frankforter; Luis M Anez; Manuel Paris; Lourdes Suarez-Morales; José Szapocznik; William R Miller; Carmen Rosa; Julie Matthews; Chris Farentinos
Journal:  J Consult Clin Psychol       Date:  2009-10
View more
  23 in total

1.  Direct-to-Consumer Marketing: A Complementary Approach to Traditional Dissemination and implementation Efforts for Mental Health and Substance Abuse Interventions.

Authors:  Sara J Becker
Journal:  Clin Psychol (New York)       Date:  2015-03-01

2.  The Appalachian Tri-State Node Experiences with the National Institute on Drug Abuse Clinical Trials Network.

Authors:  Thomas M Kelly; Dennis C Daley; Mimmie Byrne; Larry Demarzo; Doris Smith; Stephanie Madl
Journal:  Mind Brain       Date:  2011-07

3.  Perceptions of 'Evidence-Based Practice' among the Consumers of Adolescent Substance Use Treatment.

Authors:  Sara J Becker; Anthony Spirito; Roshani Vanmali
Journal:  Health Educ J       Date:  2015-04-20

4.  Relation of study design to recruitment and retention in CTN trials.

Authors:  Paul G Wakim; Carmen Rosa; Prasad Kothari; Mary Ellen Michel
Journal:  Am J Drug Alcohol Abuse       Date:  2011-09       Impact factor: 3.829

5.  Gender research in the National Institute on Drug Abuse National Treatment Clinical Trials Network: a summary of findings.

Authors:  Shelly F Greenfield; Carmen Rosa; Susan I Putnins; Carla A Green; Audrey J Brooks; Donald A Calsyn; Lisa R Cohen; Sarah Erickson; Susan M Gordon; Louise Haynes; Therese Killeen; Gloria Miele; Susan Tross; Theresa Winhusen
Journal:  Am J Drug Alcohol Abuse       Date:  2011-09       Impact factor: 3.829

6.  Ten take home lessons from the first 10 years of the CTN and 10 recommendations for the future.

Authors:  Kathleen M Carroll; Samuel A Ball; Ron Jackson; Steve Martino; Nancy M Petry; Maxine L Stitzer; Elizabeth A Wells; Roger D Weiss
Journal:  Am J Drug Alcohol Abuse       Date:  2011-09       Impact factor: 3.829

7.  Rates and influences of alcohol use disorder comorbidity among primary stimulant misusing treatment-seekers: meta-analytic findings across eight NIDA CTN trials.

Authors:  Bryan Hartzler; Dennis M Donovan; Zhen Huang
Journal:  Am J Drug Alcohol Abuse       Date:  2011-09       Impact factor: 3.829

Review 8.  Toward empirical identification of a clinically meaningful indicator of treatment outcome: features of candidate indicators and evaluation of sensitivity to treatment effects and relationship to one year follow up cocaine use outcomes.

Authors:  Kathleen M Carroll; Brian D Kiluk; Charla Nich; Elise E DeVito; Suzanne Decker; Donna LaPaglia; Dianne Duffey; Theresa A Babuscio; Samuel A Ball
Journal:  Drug Alcohol Depend       Date:  2014-01-31       Impact factor: 4.492

9.  Mortality Rates Among Substance Use Disorder Participants in Clinical Trials: Pooled Analysis of Twenty-Two Clinical Trials Within the National Drug Abuse Treatment Clinical Trials Network.

Authors:  Robert Lindblad; Lian Hu; Neal Oden; Paul Wakim; Carmen Rosa; Paul VanVeldhuisen
Journal:  J Subst Abuse Treat       Date:  2016-08-15

10.  Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependence.

Authors:  Edward V Nunes; Joshua D Lee; Dominic Sisti; Andrea Segal; Arthur Caplan; Marc Fishman; Genie Bailey; Gregory Brigham; Patricia Novo; Sarah Farkas; John Rotrosen
Journal:  Contemp Clin Trials       Date:  2016-09-28       Impact factor: 2.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.